Health Care • Biotechnology: Pharmaceutical Preparations
$1.53 ▲ +0.04
(+2.69%)
MKT CAP: $190.2M • VOL: 1.18M
52W L $1 52W H $5
ROARABLE / RQD
E • 33/100
PIOTROSKI
5 / 9
ADCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $81.4M | $70.8M | $69.1M |
| YoY Revenue Growth % | +14.9% | +2.6% | — |
| Gross Profit | $75.6M | $64.9M | — |
| Gross Margin % | 92.9% | 91.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$121.5M | -$130.7M | -$166.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$142.6M | -$157.8M | -$240.1M |
| EBITDA (Normalized) | -$121.3M | -$130.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$141.2M | -$123.8M | -$118.7M |
| Capital Expenditures (CapEx) | $264.0K | $867.0K | — |
| Free Cash Flow (FCF) | -$141.4M | -$124.7M | -$118.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $261.3M | $250.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$185.8M | -$202.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ADCT.